Alvin Lim

Special counsel, Withers KhattarWong*

Withers KhattarWong LLP is a Singapore law practice, affiliated with Withers LLP.

Alvin is special counsel in the Intellectual Property and Technology team.

An intellectual property specialist since 2007, Alvin was recognized as a leading lawyer in the field of intellectual property in the 2017 and 2018 editions of AsiaLaw Leading Lawyers. He was also cited as a Patent Star in the 2019/20 and 2020/21 editions of Managing Intellectual Property’s IP Stars in recognition of his patent litigation, patent strategy and counselling work.

Alvin’s areas of practice includes advising clients in all aspects of intellectual property and intangible asset acquisition, management, commercialization, enforcement and protection strategy across a broad range of industries and technologies spanning life sciences, medtech, telecommunications, IT, electronics, semiconductors, FMCG, food and beverage, music, fashion and design, digital technology and artificial intelligence.

Alvin has a strong IP litigation and enforcement practice, regularly acting for clients in patent, trademark, copyright and trade secrets disputes in Singapore and also cross border IP disputes. Alvin’s experience in handling pharmacological advisory and patent linkage work has seen him act for multinational pharmaceutical companies such as Eli Lilly, F. Hoffmann-LA Roche AG, OSI Pharmaceuticals, Merck & Co, Bristol-Myers Squib Pharma Co and AstraZeneca. Other notable clients Alvin has acted for include Nokia Corporation, Asahi Glass, NexPlanar Corporation, Rokko Holdings, JCS Echigo Pte Ltd, Aurigin Technology Pte Ltd, Swiss Ranks Pte Ltd, Staywell Hospitality Pty Limited, ERS Electronic GMBH, Lenzing, Virtual Map, and TMRG Pte Ltd.

Several of the cases in which Alvin has been involved in involve novel issues of law and/or have been reported in the law journals and law reports of Singapore, including:

  • Sun Electric Pte Ltd v Sunseap Group Pte Ltd and Ors [2020] SGHCR 1;
  • Sun Electric Pte Ltd v Sunseap Group Pte Ltd and Ors [2019] SGHCR 11;
  • Novartis (Jiangsu) Pte Ltd v Bristol-Myers Squib Pharma Co [2018] 3 SLR 1194;
  • Dr Babor Gmbh & Co KG & Anor v Sante De Beaute Pte Ltd [2018] SGHC 159;
  • Starwood Hotels & Resorts Worldwide Inc and Sheraton International IP LLC v Staywell Hospitality Pty Limited [2018] SGIPOS 11;
  • Rohm & Haas Electronic Materials CMP Holdings Inc v NexPlanar Corp [2017] SGHC 310;
  • Ship’s Equipment Centre Bremen GmbH v Fuji Trading (Jiangsu) Pte Ltd [2015] 4 SLR 781;
  • Invenpro (M) Sdn Bhd v JC Automation Pte Ltd [2014] 2 SLR 1045;
  • Astra Zeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd [2012] SGHC 16; [2013] SGHCR 7;
  • Hoya Corp v Asahi Glass Co Ltd [2010] SGHC 15;
  • ASM Assembly Automation Ltd v Aurigin Technology Pte Ltd [2010] 1 SLR 1;
  • Love & Co Pte Ltd v The Carat Club Pte Ltd [2009] 1 SLR 561;
  • Virtual Map (Jiangsu) Pte Ltd v Singapore Land Authority [2007] SGDC; and
  • N.V. Sumatra Tobacco Trading Company v British American Tobacco (brands) Inc [2008] SGIPOS1.

The non-contentious aspects of Alvin’s practice include conducting IP and intangible asset audits, IP registration and prosecution work, acting for clients in commercial IP transactions, drafting and review of technology contracts, providing advice on regulatory law and compliance in respect of data privacy, medical, advertising and fintech laws. Alvin has also been retained by clients as external "in-house counsel" in diverse fields such as med tech, semiconductor manufacturing, beauty and aesthetics and automation, where he worked directly with and provided legal support to business stakeholders and executives.

Focus areas





Acted for TMRG Pte Ltd and Luke’s Tavern Holdings Pte Ltd as lead counsel against Luke’s Seafood LLC and its Singapore franchisee in a trademark infringement and passing off trial in the Singapore High Court. Clients operated a fine dining establishment called "LUKE’S" and had to take action against the American F&B giant Luke’s Seafood LLC who started a "Luke’s Lobster" franchise in Singapore to avoid confusion and damage to client’s brand and goodwill.

Acted for F.Hoffmann – La Roche AG against Drug Houses of Australia Pte Ltd in a patent linkage dispute relating to a drug used to treat lung cancer and pancreatic cancer. The action resulted in a favourable outcome for client as the Defendant eventually withdrew its product license application.

Acted for Bristol-Myers Squib Pharma Co in patent linkage proceedings against Novartis (Singapore) Pte Ltd. This case resulted in a Judgment reported as Novartis (Jiangsu) Pte Ltd v Bristol-Myers Squib Pharma Co [2018] 3 SLR 1194, a high profile decision in relation to whether corrections may be made to the Registrar of Patents in correct errors in the Patents Register that captured the attention of the Singapore Patent Attorney profession.

Advocate and solicitor (Singapore), 2006

Member, Law Society of Singapore

Member, Singapore Academy of Law

Member, Inquiry Panel of the Law Society

Moderator and speaker at "Valuation of Technology Companies" presented on 19 May 2021, organized by the Singapore Academy of Law

Speaker at "NSW Going Global Program – Commercial Law and IP Legal Issues Relating to Market Entry and Global expansion", presented on 1 Apr 2021.



  • English




Regularly works with...